Human DNA topoisomerase I (hTOP1) is a highly effective new molecular target for anticancer drugs such as camptothecins (CPTs). CPTs inhibit (poison) TOP1 by trapping a covalent reaction intermediate, the ternary TOP1 cleavable complex. These TOP1 cleavable complexes represent a new type of cellular lesion highly effective in killing tumor cells. In addition to CPTs, a growing list of compounds (TOP1 poisons) (e.g. indolocarbazoles, nitidines, saintopin, morpholinyl doxorubicin, aclacinomycin A, indeno[1,2-c]isoquinolines, nogalamycin, actinomycin D, protoberberines, dibenzo[c,h]cinnolines, 2-phenylbenzimidazoles and terbenzimidazoles) have been identified to induce TOP1 cleavable complexes. Despite the clear importance of TOP1 cleavable complexes in tumor cell killing, the molecular mechanism underlying tumor cell killing by TOP1 poisons remains unclear. Our preliminary studies have suggested that at least two distinct molecular mechanisms may be involved in trapping TOP1 cleavable complexes by these different TOP1 poisons. CPTs, the prototypic TOP1 poisons, trap TOP1 cleavable complexes by specifically inhibiting the religation step of the TOP1-catalyzed breakage/religation reaction, presumably by binding to the TOP1- DNA complex at the site of DNA cleavage (religation blockers). By contrast, nogalamycin, a DNA binder with both intercalative and minor groove-directed modes of interactions, traps TOP1 cleavable complexes by inducing a distal DNA bend which favors TOP1 binding/cleavage (cleavage enhancers). The identification of two distinct modes of TOP1 poisoning by different TOP1 poisons may offer new opportunities for drug design and development. In the current application, we plan to characterize these two modes of TOP1 poisoning and to probe the differential biological responses induced by different TOP1 poisons.
The specific aims are (1) to establish a DNA curvature model for TOP1 cleavage enhancers using nogalamycin as a model, and (2) to probe the protein conformation and cellular modification of TOP1 cleavable complexes induced by different TOP1 poisons.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA077433-06
Application #
6687804
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Fu, Yali
Project Start
1998-04-01
Project End
2004-12-31
Budget Start
2004-01-01
Budget End
2004-12-31
Support Year
6
Fiscal Year
2004
Total Cost
$279,460
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Pharmacology
Type
Schools of Medicine
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Feng, Wei; Satyanarayana, Mavurapu; Tsai, Yuan-Chin et al. (2009) 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. Bioorg Med Chem 17:2877-85
Zhu, Shejin; Ruchelman, Alexander L; Zhou, Nai et al. (2006) 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 14:3131-43
Zhu, Shejin; Ruchelman, Alexander L; Zhou, Nai et al. (2005) Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents. Bioorg Med Chem 13:6782-94
Daroui, Parima; Desai, Shyamal D; Li, Tsai-Kun et al. (2004) Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death. J Biol Chem 279:14587-94
Ruchelman, Alexander L; Singh, Sudhir K; Ray, Abhijit et al. (2004) 11H-Isoquino[4,3-c]cinnolin-12-ones; novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 12:795-806
Ruchelman, Alexander L; Kerrigan, John E; Li, Tsai-Kun et al. (2004) Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: influence on topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 12:3731-42
Ruchelman, Alexander L; Zhu, Shejin; Zhou, Nai et al. (2004) Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem Lett 14:5585-9
Singh, Sudhir K; Ruchelman, Alexander L; Li, Tsai-Kun et al. (2003) Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J Med Chem 46:2254-7
Desai, Shyamal D; Zhang, Hui; Rodriguez-Bauman, Alexandra et al. (2003) Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol 23:2341-50
Yu, Younong; Singh, Sudhir K; Liu, Angela et al. (2003) Substituted dibenzo[c,h]cinnolines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem 11:1475-91

Showing the most recent 10 out of 21 publications